Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study

[1]  A. di Caro,et al.  Active Pulmonary Tuberculosis in Elderly Patients: A 2016–2019 Retrospective Analysis from an Italian Referral Hospital , 2020, Antibiotics.

[2]  Jae Ho Lee,et al.  The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis , 2020, PloS one.

[3]  R. Okuda,et al.  Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[4]  O. Kon,et al.  Time to diagnosis of tuberculosis is greater in older patients: a retrospective cohort review , 2019, ERJ Open Research.

[5]  K. Nemoto,et al.  Comparison of adverse effects in tuberculosis patients over 80 years of age with and without pyrazinamide treatment , 2017 .

[6]  W. Su,et al.  Determinants of mortality in elderly patients with tuberculosis: a population-based follow-up study , 2017, Epidemiology and Infection.

[7]  L. P. Ormerod,et al.  Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period. , 2016, The International Journal of Tuberculosis and Lung Disease.

[8]  R. Chaisson,et al.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Manju Sharma,et al.  Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study , 2016, BioMed research international.

[10]  Chun-wen Cheng,et al.  The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide , 2016, Clinical interventions in aging.

[11]  Jann-Yuan Wang,et al.  Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study , 2015, European Respiratory Journal.

[12]  Bachti Alisjahbana,et al.  Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. , 2014, The Lancet Diabetes and Endocrinology.

[13]  Ying Zhang,et al.  Mechanisms of Pyrazinamide Action and Resistance. , 2014, Microbiology spectrum.

[14]  I. Oh,et al.  Clinical characteristics and treatment outcomes of tuberculosis in the elderly: a case control study , 2013, BMC Infectious Diseases.

[15]  N. Horita,et al.  [Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide]. , 2013, Kekkaku : [Tuberculosis].

[16]  Yi-Shin Huang.  Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury , 2007, Expert opinion on drug metabolism & toxicology.

[17]  P. Hsueh,et al.  Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas , 2006, Thorax.

[18]  D. Menzies,et al.  Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[19]  C. Lam,et al.  Tuberculosis in Older People: A Retrospective and Comparative Study from Hong Kong , 2002, Journal of the American Geriatrics Society.

[20]  S. Rajagopalan,et al.  Tuberculosis and aging: a global health problem. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. H. Vargas,et al.  Does aging modify pulmonary tuberculosis?: A meta-analytical review. , 1999, Chest.

[22]  T. Schaberg,et al.  Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. , 1996, The European respiratory journal.

[23]  P. Davies.  Tuberculosis in the Elderly , 1996, Drugs & aging.

[24]  S. Lemeshow,et al.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study , 1993 .

[25]  Sati Mazumdar,et al.  Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale , 1992, Psychiatry Research.

[26]  T. Takemura,et al.  A case of pyrazinamide-associated myoglobinuric renal failure. , 1991, Japanese journal of medicine.

[27]  C. D. Morris.  Pulmonary tuberculosis in the elderly: a different disease? , 1990, Thorax.

[28]  S. Sanwikarja,et al.  Tubulointerstitial nephritis associated with pyrazinamide. , 1989, Netherlands Journal of Medicine.

[29]  B Bégaud,et al.  Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France , 1985 .

[30]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[31]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[32]  N. Horita,et al.  Currently Used Low-Dose Pyrazinamide Does Not Increase Liver-Injury in the First Two Months of Tuberculosis Treatment. , 2015, Internal medicine.

[33]  A. Eschalier,et al.  [Managing the adverse events of antitubercular agents]. , 2011, Revue des maladies respiratoires.

[34]  S. Lemeshow,et al.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.

[35]  J Jouglard,et al.  [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. , 1985, Therapie.

[36]  Britishthoracicsociety.  A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. , 1984, British journal of diseases of the chest.

[37]  H. V. Smith.  TUBERCULOUS MENINGITIS. , 1964, International journal of neurology.